Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of the current study is to investigate the efficacy, safety and tolerability of
BI 1356 (Linagliptin) (5 mg / once daily) compared to placebo given for 24 weeks as initial
combination therapy with pioglitazone 30 mg in patients with type 2 diabetes mellitus with
insufficient glycaemic control.